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DepressionisacommoncomplicationofParkinson’sdisease(PD)withconsiderableimpactonpatients’qualityoflife.However,at
presentthemostappropriatetreatmentapproachisunclear.TherearelimiteddataonantidepressantmedicationsinPD-associated
depression (dPD) and those availablesuggest limited eﬃcacy and tolerability of these drugs. Cognitive behavioural therapy (CBT)
has been shown to be an eﬀective treatment of depressive disorders. Treatment of dPD with CBT may pose particular challenges,
including possible diﬀerent pathophysiology, physical and mental comorbidities, and barriers to treatment through disability,
which do not allow simple transfer of these results to patients with dPD. However, a number of case reports, case series, and small
pilot studies suggest that this is a promising treatment for patients with PD. We here summarise the published evidence on this
treatment in dPD.
1.Introduction
Although Parkinson’s disease (PD) is diagnosed on the basis
of the classic features of motor disturbance [1, 2], it is now
widely recognised that nonmotor symptoms are common,
and occur across all stages of the disease [3]. Depressive
disorders aﬀect approximately 40% of patients with PD
[4–7]. They are linked to functional impairment, cognitive
decline, and faster disease progression and are the main
determinant for poor quality of life in PD [8–12]. They
are also associated with increased health care costs in the
population, raising both direct and indirect costs [13, 14].
Despite this established negative impact, depressive
symptoms in PD are underrecognised and undertreated in
clinical practice [15]. Additionally, there is a lack of well-
designed studiesthat can guide clinical management of these
patients. So far, only a few double-blind, placebo-controlled
trials have speciﬁcally assessed antidepressant use for PD
patients [16, 17], and even fewer research data exist on
nonpharmacological approaches for PD-associated depres-
sion [18, 19]. As a result, evidence-based recommendations
and consensus on the best treatment choice for this patient
population are scarce [20].
The previous pharmacological studies have shown that
medication traditionally used for depression in older people
(e.g., SSRIs) may not be more eﬀective than placebo in PD,
or may be diﬃcult to utilise in this age group due to the
aggravation of orthostatic hypotension, constipation, and
cognitive impairment (e.g., tricyclic antidepressants) [21–
23]. In addition, depressive symptoms in PD often do not
fulﬁl the criteria for major depression, and it may therefore
not be appropriate to treat such cases with medication.
Cognitive behaviour therapy (CBT) is well established
for the treatment of depression, and there is considerable
evidence from depression without PD that CBT in this
patient group is eﬀective. This has recently been shown
to include older patients [24]. However, it is recognised
that dPD may diﬀer from depression without PD, both2 Parkinson’s Disease
in terms of aetiology and patient characteristics. Patients
with PD are typically older, have physical impairment and
subtle cognitive deﬁcits, and therefore delivery, feasibility,
and outcome of CBT may be diﬀerent in patients with PD.
Inthispaperweconsidertheroleofcognitive-behaviour-
al therapy (CBT) as a potential approach for patients with
PD and associated depression, based on a systematic review
of published studies in the area.
2.Methods:ScopeofThisReview,Search
Strategy,and SelectionCriteria
We included all types of studies of CBT for depressive
symptoms in PD patients (including single case studies, case
series, and pilot studies of any duration), and systematically
reviewed the evidence for eﬀectiveness of CBT in dPD.
References for this review were identiﬁed by searching
PubMed for the last 40 years using the search terms “Parkin-
son’s disease” or “Parkinsonism” or “Parkinsonian” and
“Depression” or “aﬀective disorders” or “mood disorders”;
these results were cross-referenced with the search terms
“CBT” or “cognitive therapy” or “psychotherapy”. In addi-
tion, the following databases were searched using the same
strategy: MEDLINE (1950 to November 2010), EMBASE
(1980 to November 2010), EMBASE Classic (1947 to 1979),
PsychINFO (1806 to November 2010), PsycEXTRA (1908 to
November 2010), PsycBOOKS (1806 to November 2010),
Web of Science (January 1981 to November 2010), and
AMED (January 1985 to November 2010). All abstracts
were read, and the articles found were further screened and
selected as follows: only articles in the English language
were selected, and only those articles reporting data on
adults using cognitive or cognitive behavioural therapy for
dPD. We also searched the Cochrane Library for systematic
reviews. The reference lists of the selected articles with
the above strategy were checked for additional materials
whenappropriate.Handsearching ofneurologic,psychiatric,
and related literature was also performed. Moreover, online
resources were searched systematically, including Medscape,
NICEclinicalguidelines,DepartmentofHealthpublications,
and registers of upcoming trials.
All the selected studies were assessed for their method-
ological quality. Key areas of evaluation included the accu-
rateness/robustness of the diagnoses of depressive symptoms
and idiopathic PD, the outcome measures used and their
validity in PD and PD depression (with a special attention
on the rating scales for evaluating changes in depression
severity), the accurate description of the intervention used,
and quantiﬁcation of cognitive impairment and other
comorbidities.
3.Results
We screened 1579 article abstracts in total; the search yielded
a number of review articles and 15 studies of CBT for
depression in PD patients. Of these, 2 were single case
studies, and the rest were cases series and pilotstudies, which
are depicted in Table 1 a n dp r e s e n t e da n dd i s c u s s e di nt h e
rest of this review.
3.1. Pilot Studies and Case Series. Dreisig et al. [25]r e p o r t e d
a pilot study to explore the eﬀects of CBT in 9 patients
with PD compared to 70 matched control subjects who
received treatment as usual. The 3-month CBT program
included self-help and individual sessions. After this period,
based on the Psychological Proﬁle Questionnaire (includ-
ing depression scores), the group receiving CBT showed
signiﬁcantly more improvement (P<. 01) compared to
the control group. However, this study was not aimed
speciﬁcally at depression in PD. Overall, the percentage of
moderate or major depression amongst PD patients was low
(∼10%), and no PD patients in the CBT group had major
depression. Methodological problems also include lack of
randomisation, small sample size, and choice of instrument
(not a validated depression scale). The study was also limited
to young PD patients, which were self-referred, which could
have led to selection bias. It is also important to note that
the content of CBT was not described in detail making
evaluation diﬃcult. Nevertheless, the study by Dreisig et al.
provided data in a small series of patients in a naturalistic
setting with some control data and suggests that CBT might
be eﬀective for patients with PD.
Dobkin et al. explored the feasibility of using CBT to
treat depression in an open study in 15 PD patients [26].
All patients had major depression based on DSM-IV and
no evidence of dementia, psychosis, or signiﬁcant motor
ﬂuctuations. The content and delivery of treatment was
developed via a previous case series [35]. Patients received
10–14 sessions of personalized CBT incorporating relaxation
techniques and sleep hygiene education. Treatment delivery
was modiﬁed to aid memory retention, and caregivers
attendedseparate educationalsessions. The Hamilton Rating
Scale for Depression (HAM-D) and the Beck Depression
Inventory (BDI) were used as the primary outcome mea-
sures, while negative thoughts (Inference Questionnaire;
IQ), anxiety (State Trait Anxiety Inventory; STAI), and
perception of social support (Adaptive Inferential Feedback
Questionnaire, AIFQ) were evaluated as secondary outcome
measures. Of the 13 patients who completed the study, 80%
experienced signiﬁcant reductions in depressive symptoms
(HAM-D; BDI, P<. 0001). A signiﬁcant decrease was
also noted in negative inferences (IQ, P<. 001), while
the perception of social support was increased signiﬁcantly
(AIFQ, P<. 001). Despite the methodological limitations
of this study (lack of control group, small sample size, and
no formal assessment of the contribution of caregivers),
the detailed study design, inclusion of qualitative methods,
involvement of caregivers, exclusion of patients with motor
ﬂuctuations and the delivery of treatment by a trained
CBT therapist, provide good preliminary evidence as to
the feasibility and potential eﬀectiveness of this treatment
modality for dPD.
Another uncontrolled study of CBT in targeting depres-
sion within the context of PD was recently reported recently
by Farabaugh et al. [27]. Eight depressed patients were
enrolled into an open study of 12-week individually tailored
CBT treatment. The authors reported a signiﬁcant linear
decrease in mean Hamilton Rating Scale for Depression
(HAM-D) scores over the treatment period. At the studyParkinson’s Disease 3
Table 1: Summary of studies reviewed focusing on CBT for patients with PD and depression.
Study Sample size Intervention Delivery Outcome measures
Dreisig et al. [25]∗ 79 PD: 9 CBT; 70 control Self-help & tailored CBT Author (trained) Psychological Proﬁle
Questionnaire, SDS
Dobkin et al. [26]1 5 P D ; 1 5 c a r e g i v e r s Tailored CBT &
caregiver program Clinical psychologist HAM-D, BDI, IQ, STAI,
AIFQ
Farabaugh et al. [27]8 P D Individual CBT
treatment Author (trained) HAM-D
Veazey et al. [28]∗
10 PD; randomized into
CBT group or support
group (control)
Telephone-administered
CBT Author (trained) MMSE, PHQ-9, BAI,
PDQ-39, SCID
Leroi and King [29]8 P D Individual CBT
treatment
Consultant clinical
psychologist GAS, unreported scales
Simons et al. [30]2 2 P D ; 1 4 C a r e g i v e r Educational program
withCBT elements Not reported SDS, PDQ39, participant
evaluation
A’Campo et al. [31]6 4 P D ; 4 6 C a r e g i v e r Educational program
withCBT elements Not reported Dutch version of PDQ-39
and EQ-5D, SDS, VAS
Macht el al. [32] 151 PD Educational program
withCBT elements Author (trained)
Patients’ ratings of the
comprehensibility and
feasibility of the
programme as well as
mood ratings before and
after each session
Cole and Vaughan [33] 5 PD CBT Author (trained) BDI-II, GDS15, PDQL
Feeney et al. [34] 4 PD CBT Not reported BDI-II
Dobkin et al. [35]3 P D ; 3 c a r e g i v e r s Tailored CBT &
caregiver program Not reported HAM-D, BDI, IQ, STAI,
AIFQ
Macht et al. [36] 3 PD Tailored CBT Author (trained) Clinician’s Assessment
Fitzpatrick et al. [37]1 2 P D M B C T A u t h o r
Not formal outcome
measures; Interpretative
phenomenologicalanalysis
Gupta and Bhatia [38] 1 PD CBT Author (trained) Clinician’s Assessment
Laidlaw et al. [39] 1 PD CBT Author (trained) Clinician’s Assessment
∗Studieswith a control group.
AIFQ:Adaptive InferentialFeedback Questionnaire;BDI: BeckDepressionInventory; CBT:Cognitive BehaviouralTherapy;CES-D:CentreforEpidemiologic
Studies Depression Scale; GAS: Global Assessment Scale; GDS: Geriatric Depression Scale; HAM-D: Hamilton Rating Scale for Depression; HRQL: Health
Related Quality of Life; IQ: Inference Questionnaire; MBCT: mindfulness-based cognitive therapy; MMSE: Mini-mental State Examination; PD: Parkinson’s
Disease; PDQL: Parkinson’s Disease Quality of Life Questionnaire; PDQ39: Parkinson’s Disease Questionnaire 39; PHQ-9: Patient Health Questionnaire-
9; SCID: Structured Clinical Interview for DSM-IV; SDS: Zung Self-Rating Depression Scale; STAI: Spielberger State-Trait Anxiety Inventory; VAS: Visual
Analogue Scale.
endpoint more than half of the patients (57%) met the
criteria for complete remission. With the same limitations as
the above studies, this pilot study also adds to the suggestion
that CBT may be beneﬁcial in this population of patients
and may be an alternative or adjunct to pharmacological
treatment strategies.
Veazey et al. [28] reported a controlled study of
telephone-administered CBT for PD patients with depres-
sion and anxiety. At baseline, the ten patients who took part
were assessed using MMSE, Patient Health Questionnaire-9
(PHQ-9),BeckAnxiety Inventory (BAI),Parkinson’s Disease
Questionnaire-39 (PDQ-39), and the Structured Clinical
Interview for DSM-IV (SCID). Based on BAI and PHQ-9,
half of the patients had anxiety and depression, 4 (40%) had
only anxiety and 1 had only depression. Study participants
were randomizedintoeitheraCBTgrouporasupportgroup
(control).The CBTgroupsreceived1in-person CBTsession,
followed by 8 weekly telephone-delivered CBT sessions.
Sessions covered depression and anxiety education, relax-
ation training, cognitive therapy, problem solving, activity
scheduling, andsleep-management skills. Thesupportgroup
received 8 weekly phone calls from a therapist, during which
the therapist followed a script including questions about the
patient’sgeneralwellbeing; psychotherapy elementswere not
included. Whilst this was a pilot study on the feasibility
of CBT with descriptive data, there was an improvement
in depression (based on changes in PHQ-9 scores) for
both groups following treatment and at 1-month followup.
The CBT group was more improved, but with a small
diﬀerence,compared tothe supportgroup. Similarly,anxiety4 Parkinson’s Disease
improved for both groups, with a greater improvement
in the CBT group. The study is the ﬁrst to use remote-
delivered CBT for PD patients and to use a control group
with a nonspeciﬁc “talking therapy”. Delivering CBT by
telephone allows participants more ﬂexibility in scheduling
and keeping weekly appointments than in-person meetings.
However, this approach also poses a number of problems; in
particular,itmaybemorediﬃculttokeeppatientsmotivated
and active, to ensure that patients complete homework and
understand treatment sessions. Thus, it may be preferable to
test the eﬃcacy of CBT for PD-associated depression using
standard therapy protocols (i.e., face-to-face) before using
modiﬁed approaches with potential confounders.
In an abstract, Leroi and King [29] reported an uncon-
trolled pilot study to evaluate the feasibility of modiﬁed CBT
for PD patients with depression and/or anxiety based on
DSM-IV and Geriatric Depression Scale (GDS). The study
included 5 patients with idiopathic PD, two of whom had
major depressive disorder, one nonmajor depression, and
two mixed anxiety and depression at study start. CBT (6–10
sessions) was delivered by a consultant clinical psychologist
and relevant changes in depression/anxiety were measured
using the Global Attainment Scale (GAS) and other unre-
ported scales. Depression and anxiety scores improved in
all participants, with 100% reaching subthreshold levels
for clinical signiﬁcance. The mean GAS score reﬂected
moderate to marked improvement on pretreatment self-
selected outcome goals, while the therapy was found to be
well-tolerated and feasible. Conclusions from this study are
diﬃcult to draw as there were only overall 5 patients, no
control group and the validity of the GAS in this patient
group has not been tested. In addition, the authors reported
modiﬁcations to the standard CBT protocol, but these were
not detailed in the abstract.
Simons and colleagues [30] reported an eight-session
group educational program, called the EduPark, that was
developed to promote coping strategies and address com-
mon psychosocial problems in PD patients and caregivers.
EduPark covers many of the skills included in standard CBT
[36] and was evaluated in a pilot study of 36 participants.
Patients completed a self-rating depression scale (SDS)
before and after the program [40]. EduPark yielded short-
term improvements in visual analogue ratings of mood
and was favorably evaluated by participants. However, no
signiﬁcant eﬀects on quality of life or depression as assessed
on the SDS were found in patients or caregivers [30]. Studies
from other participating countries reported similar ﬁndings
in overall 151 patients with improvement of psychosocial
functioning and mood assessment on a visual analogue scale
but not on the SDS [32]. The limitations of this study, in
addition to the lack of control group, include uncertainty
whether any of the enrolled patients had a formal diagnosis
of depression at baseline. In addition, although educational
programs are of great importance, by deﬁnition they are
more disperse and less intensive than individually tailored
CBT. Achievement of signiﬁcant changes in depression may
require a more intensive and/or longer period of treatment.
The two uncontrolled studies conducted during the
development of EduPark [30, 32] were more tailored to
evaluate its feasibility rather than its eﬀectiveness. A’Campo
et al. recently described a RCT which evaluated the eﬀec-
tiveness of this educational programme in PD patients and
their caregivers from The Netherlands [31]. Sixty-four PD
patients and 46 caregivers participated and were allocated
to either the intervention group (receiving eight weekly, 90-
minute duration sessions) or the control group (receiving
usual care). The primary outcomes measure of this trial
were psychosocial burden, depression and QoL of both
patients and caregivers and depression (using the SDS).
Participants in both groups were also asked to rate their
present mood before and after each individual session on a
100-point visual analogue scale (VAS). No signiﬁcant eﬀects
on the primary outcome measures of the patients were
found after the completion of the programme. A marginally
signiﬁcant trend of improvement was only observed in the
PDQ-39, favouring the intervention group (P = .015).
However, based on the VAS, patients’ mood was found to
be signiﬁcantly improved from before to after sessions (P<
.001). Moreover, concerning the caregivers’, psychosocial
problems and need for help of the intervention group were
signiﬁcantly improved compared to the control group. The
improvements on mood as highlighted by the VAS indicate
thatthepatientsin theinterventiongroupfeltbetterafterthe
session. However, this scale represents an oversimpliﬁcation
of mood measuring and there was no comparison to a
control group. Despite the randomised controlled nature
of this trial, the methodological weaknesses of this trial
include the fact that the participants had no or only minimal
depressive symptoms, which were assessed by a relatively
insensitive instrument (SDS). Moreover, the authors do not
report how the diagnosis of the depressive disorders was
made in this patient population (apart from the depression
rating scale score) and how PD was diagnosed.
Cole and Vaughan [33] reported a case series where brief
home-based CBT was used to treat depression in the context
of PD. Five patients aged 54–82 years were referred for treat-
mentfrom amovementdisordersclinicfollowing adiagnosis
of possible depression (based on Geriatric Depression Scale-
GDS).Threeoutof5patientshadBeckDepressionInventory
(BDI) scores indicating major depression, and none of them
had dementia. CBT was protocol driven and based on a
self-help booklet. One 60-minute CBT session per week
was allocated for each section of the booklet, over 7 weeks.
Following treatment, there were reductions in depression
scores. However, these were marginal in the patients with
less severe depression and changes in depression scores were
not accompanied by changes in QoL. Lack of meaningful
improvement in two patients was felt to be at least partly
related to intervening illness and personal factors. This study
is one of the few which reported how PD was diagnosed (UK
Parkinson’s Disease Society Brain Bank). However, diagnosis
of depressive disorder was not made based on DSM-IV
criteria. It is possible that the small patient number and the
short baseline durations hamper the sensitivity of detecting
an eﬀectiveness of CBT. However, the results may indicate
that less severe depression may be less responsive to this
intervention.Parkinson’s Disease 5
The eﬀects of group CBT for depression and anxiety in
PD were also assessed in a small case series of 4 patients
aged 56–81 years [34]. Participants were not cognitively
impaired (based on Mini-mental Mental State Examination-
MMSE), three of them had major depression [41], while one
had a dysthymic disorder based on the Mini-International
Neuropsychiatric Interview (MINI) [42]. Minor adaptations
to the delivery of CBT were made, such as a reduction on
the amount of writing to account for motor diﬃculties.
Treatment resulted in a clinically signiﬁcant improvement in
depression in 3 out of 4 patients according to the BDI. This
case series is documenting the feasibility of CBT for patients
with PD and depression with maintenance of gains at the
1-month followup. Again, the small sample size, the lack of
control, and exclusion criteria make the applicability ofthese
ﬁndings to other patients with PD-associated depression
uncertain. One other disadvantage of this particular study
is that it does not report who delivered CBT, or whether a
CBT protocol was used; therefore, the content of treatment is
uncertain. Onepatientin this study hadbeen diagnosed with
PD 12 years ago, compared with 1–3 years for the rest of the
participants, and this patient did not show improvement. At
presentitisunclearwhethermoreadvancedPDisapredictor
of nonresponse to CBT.
Dobkin et al. [35] reported a case series of 3 patients
with PD meeting the DSM-IV criteria for major depression
(and with no evidence of dementia or psychosis). The
primary outcome measure used was Hamilton Rating Scale
for Depression (Ham-D). Patients received 12–14 sessions
of individually tailored CBT. After identifying stressors that
appeared to contribute to depressed mood, short and long-
term plans were developed to minimize stress and maximize
QoL by emphasing behavioural activation and problem-
solving strategies around physical limitations. All patients
were experiencing sleep diﬃculties, so sleep hygiene tech-
niques were incorporated. In parallel, relaxation techniques,
such as diaphragmatic breathing, were also incorporated to
address anxiety and somatic complaints. Treatment delivery
was modiﬁed when necessary to aid memory retention.
Patients and caregivers evaluated positively the overall
treatment program. All patients achieved ∼50% reduction
in depression based on HAM-D and BDI, maintained at
1-month follow-up. HAM-D and BDI endpoints for two
patients indicated only mild depression, and all participants
demonstrateddecreasednegativecognitionsbasedonIQand
BDI. The authors later reported the results of a large pilot
study based on these results (see above).
Another case series of 3 self-referred PD patients treated
with CBT were reported by Macht and colleagues [36]. The
patients diﬀered in age, disease duration, disease severity,
and disability, whilst none showed signs of cognitive impair-
ment. CBT was tailored to each patient via formulation,
and adjunctive techniques were used, such as strategies to
cope with motor ﬂuctuations. Notably, only one patient
was reported to have depressive symptoms, although their
pre/posttreatment severity was not reported. The authors
reported that all patients improved in their ability to cope
with their disease following CBT, but this eﬀect was not
quantiﬁed. The limited information provided in this study
regarding the CBT intervention, the patient group and aim
of the study (improving coping with PD), combined with
the small sample size make it diﬃcult draw conclusions
regarding the eﬀect of CBT of dPD in this population.
An exploratory study was recently reported by Fitz-
patrick and colleagues which analysed the experiences of 12
PD patients after an 8-week course of mindfulness-based
cognitive therapy (MBCT) [37]. This type of psychological
therapy combines elements of both cognitive therapy and
mindfulness technique originating from Eastern spiritual
and philosophical tradition. Mindfulness prioritizes learning
how to pay attention on purpose, in the present moment
and without judgement. In this framework MBCT is built
around accepting thoughtsand feelings in a nonjudgemental
way with the aim of correcting cognitive distortions (rather
than trying to suppress and avoid them) [43]. The authors
of this study made it clear that they did not intend to assess
the eﬀectiveness of MBCT using formal outcome measures,
but to gather preliminary evidence of its acceptance and
perceivedhelpfulnessfrompatientswithPD[37].Interpreta-
tive phenomenological analysis was the qualitative approach
chosen for the analysis of emerging themes in this study
(summarised from author’s transcripts, compared against all
cases, and also analysed by a second author). The analysis
of both pre- and postcourse interviews, yielded 4 major
themesincludingchanging patternsofcoping,theroleofthis
intervention in consolidating already existing coping skills in
the context of loss, the importance of group support eﬀects
and the dualism of experience between PD and mindful
meditation. The results of this study should be evaluated
under the framework of its original purposes, design, and
methodology. Overall, it demonstrated the acceptability of
MBCT in a group of patients with PD (based on the
positive/supportive informal feedback from the participants
and the well attendance of subsequent “catchup” groups).
Moreover, this study analysed in depth what were the key
factors making this course successful. Unfortunately, there is
little information of the depressive symptomatology of the
participants. Nine patients were found to have clinical levels
of distress in one or more of the subscales of depression,
anxiety, and stress evaluated by the Depression Anxiety and
Stress Scales (DASS). This is the ﬁrst study of MBCT in the
context of PD suggesting this intervention may be useful in
future intervention studies, and the emerging themes of this
intervention can also help understand and enhance patterns
of coping with PD.
3.2. Case Studies. Gupta and Bhatia [38] treated a 90-year-
old PD patient with depression and suicidal ideation using
home-based CBT. The focus of CBT was in reinforcing
the patient’s positive interactions with his daughter (the
caregiver) and increasing his participation in enjoyable
activities. CBT indeed decreased the patient’s depressive
symptoms, improved interactions with his caregiver, and
increased activity levels. Laidlaw et al. [39]r e p o r t e dt h e
eﬀect of CBT in a patient with anxiety, depression, and
insomnia following his diagnosis with PD. The patient had
marked resting tremorin hisright hand, reducedpleasurable
activities and he had stopped going out unaccompanied.6 Parkinson’s Disease
Antidepressant medication had little eﬀect; in contrast CBT
reduced depression, anxiety, and insomnia, but the largest
gains were in activity levels. The authors emphasise the
importance of making interventions addressing the speciﬁc
diﬃculties of the patients. For example, the patient in this
paper became embarrassed and his mood dropped when his
tremor prevented him from performing motor tasks. By the
end of treatment, the patient was more willing to confront
embarrassing situationsand useCBTtechniquestochallenge
negative thought patterns [39].
4.Discussion
We identiﬁed and described 15 studies on the application of
CBT in depressed PD patients. The majority of the studies
reported functionally important improvements using this
treatment strategy to target depressive symptoms in patients
with PD, some with large eﬀect sizes. Whilst these data
are encouraging, at present there are no large randomised
c o n t r o lt r i a l s( R C T s )i nt h i sa r e aa n dt h el a r g e s ts t u d y
included overall 15 patients (excluding the studies using
education programmes rather than CBT ipse)[ 26]. Due
to the small patient sample sizes, the results from these
pilot studies and case series may overstate the eﬀect of this
intervention. Conclusions from these trials therefore have
to be cautious, particularly given the large placebo eﬀects
known to exist in both depression and PD. Interpretation of
the above studies should also take into account the following
considerations.
The evaluation of CBT studies poses particular chal-
lenges. CBT is not a single, standard form of therapy,
but, whilst including a core CBT strategy, incorporates a
collection of diﬀerent psychotherapeutic approaches and
components. This makes it diﬃcult to compare diﬀerent
studies, as they may have used diﬀerent CBT approaches. In
addition, many published studies do not provide adequate
details of the CBT intervention complicating comparison
further. For example, the intervention may not have con-
tained the same noncore aspects of CBT; and treatment
outcomes may be attributable to adjunctive techniques such
as exercise or relaxation. However, despite this variation, all
studies focusing on the application of CBT incorporate the
same core elements. CBT is deﬁned as a form of therapy
that focuses on the relationship between thoughts, feelings,
and behaviours. As such, even with many variations in its
application from person to person, CBT is distinct and very
distinguishable from other psychotherapeutic approaches
(e.g.,interpersonal,psychodynamic, etc.).Inthiscontext,the
aspects and elements of CBT that are most beneﬁcial are
likely to vary for each individual patient.
Thus, treatment is typically tailored to patients. In
clinical practice, CBT often uses protocols which have been
developed for speciﬁc disorders (e.g., depression, anxiety,
etc.). However, the ﬁrst stage of CBT is patient assessment
and the development of a formulation—a working model
of the patient’s problems. How the patient is treated, and
the selection of therapeuticinterventions, depends upon this
formulation. Formulation allows CBT theory to be applied
to unique individuals with distinct patterns of thoughts and
emotions. In this manner, CBT may be based on a protocol,
but it is tailored to each patient. As new information
emerges during treatment the formulation continues to
evolve. The formulation informs the selection of speciﬁc
cognitive, behavioural, and physical interventions. Whilst
this introduces a certain variability, this is also one of the
advantages of CBT. Other advantages of CBT include its
structured, time-limited, and goal-oriented approach, the
lack of medication side eﬀects and long-term eﬀects even
after the treatment has been completed [44, 45].
Further methodological considerations in evaluation
of the available data include the variation in reporting
PD diagnosis and few studies used the UK Parkinson’s
Disease Society Brain Bank or other standardized criteria.
In addition, current studies are likely to have been included
in highly motivated, cognitively relatively intact and less
disabled patients. However, it is currently unclear whether
and to what extent severity of PD or other disease variables
suchas mild cognitive impairmentinﬂuencethefeasibility or
eﬀectiveness of this intervention, and whether this treatment
approach is suitable across disease stages. Several studies
report excluding patients with diagnoses of dementia, but
do not report levels of cognitive impairment [26, 33, 35].
It is possible that subtle cognitive impairments could aﬀect
treatment outcomes. However, the exclusion of cognitively
impaired patients also limits the applicability of studies to
PD populations, where rates of cognitive impairment are
high. A further important consideration is the inclusion of
motor ﬂuctuations. Only one study excluded patients with
motor ﬂuctuations [26]. “Oﬀ” periods are associated with
acute episodes of depression and anxiety and could therefore
confound treatment outcomes [46]. If not excluded, patients
with motor ﬂuctuations should be assessed during “on”
periods [47].
Whilst diagnosis of depression in PD patients was gener-
ally made based on standard criteria (with their limitations
for use in PD) rather than rating scales, severity varied and a
wide range of depression rating scales were used as outcome
measures in the diﬀerent studies. Given the signiﬁcant
symptom overlap between depression, parkinsonism, and
apathy in these patients, it is currently unclear which scale is
the best choice in a trial of CBT in dPD [47]. However, given
that CBT is unlikely to inﬂuence underlying parkinsonism,
this treatment is less likely than some medications to
improvedepressionratingscalescoresthroughimprovement
of nondepression features of PD. At present it is also
unclear whether CBT may be useful for major depression or
depressive disorders not fulﬁlling these criteria.
5.Conclusions
In summary, whilst additional data from large RCTs are
needed to establish the eﬃcacy of CBT in the management
of depression in patients with PD, the available evidence,
even with the above limitations, is encouraging for the
eﬀectiveness of CBT as an option in this patient population.
In addition to establishing feasibility and eﬃcacy of CBT
in dPD in large RCTs, there are a number of questions
remaining to be unanswered in future studies, including toParkinson’s Disease 7
what extent the results of these studies can be translated
and applied to the PD patients with cognitive impairment,
whether this type of treatment is feasible in patients with
motor and nonmotor complications, how to best assess
outcome, patients of what severity of depression should be
included and whether CBT needs to be modiﬁed for patients
with PD. If shown to be eﬀective in large RCTs, CBT could
potentially provide a better possible nonpharmacologic
treating option for clinicians for the treatment of depression
inPD,eitherwhen pharmacotherapyfails, incombinationor
as an alternative to pharmacological treatment of dPD.
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